Merck-Serono signs global agreement with Beijing’s BeiGene on BeiGene-290, an antitumor drug

Nov 20, 2013

Under the contract, Merck-Serono and BeiGene (China Baiji Sino Biological Technology Co.) will jointly develop and market BeiGene-290, a poly-ADP ribose polymerase (PARP) inhibitor.

China Bio news release, November 20, 2013

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny